HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Background: Hepatic arterial infusion chemotherapy (HAIC) and Transarterial chemoembolization (TACE) both showed good local efficacy in advanced or unresectable hepatocellular carcinoma (HCC). We performed a systematic review and meta-analysis to compare the effect of HAIC with TACE in patients with unresectable HCC. Methods: Clinical trials, which were about HAIC or TACE in Patients with unresectable HCC, were identified by searching PubMed, Medline, and EMBASE from January 2010 to March 2022. A meta-analysis was performed to analyze HAIC in comparison with TACE. Treatment response, 1-year overall survival (OS), 2-year OS and serious adverse events were evaluated in this meta-analysis. Results: This meta-analysis included 6 studies. Objective response rate or Partial response in the HAIC group was significantly more than that in the TACE group (P < .05). But, stable disease showed no difference between the 2 groups (P = .52). Disease control rate in the HAIC group was better than that in the TACE group (P < .05). Progressive disease in the HAIC group was less than that in the TACE group (P < .05). In 1-year OS, there was no significant deterioration between the 2 groups (P = .53). There was not significant difference in 2-year OS between the 2 groups (P = .05). serious adverse events in the HAIC group was significantly less than that in the TACE group (P < .05). Conclusion: To some degree, HAIC may be a better therapeutic method in patients with unresectable HCC than TACE.

[1]  Peihong Wu,et al.  Infiltrative Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Versus Hepatic Arterial Infusion Chemotherapy , 2021, Frontiers in Oncology.

[2]  Bao-quan Cheng,et al.  Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. , 2021, Hepatobiliary & pancreatic diseases international : HBPD INT.

[3]  Li Xu,et al.  Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Song,et al.  Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. , 2021, Bioscience trends.

[5]  K. Yoshioka,et al.  Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma , 2021, JGH open : an open access journal of gastroenterology and hepatology.

[6]  Yun-fei Yuan,et al.  Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma , 2021, Annals of surgery open : perspectives of surgical history, education, and clinical approaches.

[7]  S. Park,et al.  MRI Features for Predicting Microvascular Invasion of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis , 2021, Liver Cancer.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  M. Soresi,et al.  Benign and malignant mimickers of infiltrative hepatocellular carcinoma: tips and tricks for differential diagnosis on CT and MRI. , 2020, Clinical imaging.

[10]  Huey-Shyan Lin,et al.  Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma , 2020, Medicine.

[11]  Xiao-Ting Li,et al.  Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma , 2020, World journal of gastroenterology.

[12]  P. Whorwell,et al.  Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. , 2020, Gastroenterology.

[13]  B. Xing,et al.  Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis , 2020, CardioVascular and Interventional Radiology.

[14]  G. Lippi,et al.  Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). , 2019, European journal of public health.

[15]  T. Murakami,et al.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[16]  O. Yokosuka,et al.  Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments , 2019, Patient preference and adherence.

[17]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[18]  K. Awai,et al.  Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial , 2018, BMC Cancer.

[19]  Rachida Lebtahi,et al.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. , 2017, The Lancet. Oncology.

[20]  Wei Wei,et al.  Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study , 2017, Chinese journal of cancer.

[21]  D. Stocken,et al.  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. , 2017, The lancet. Gastroenterology & hepatology.

[22]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[23]  Amber L. Simpson,et al.  Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis. , 2017, Journal of the American College of Surgeons.

[24]  Jia-hong Dong,et al.  Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta‐analysis , 2016, ANZ journal of surgery.

[25]  Stefano Brocchi,et al.  Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma? , 2016, Radiology.

[26]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[27]  S. Saab,et al.  Management of hepatocellular carcinoma with portal vein thrombosis. , 2015, World journal of gastroenterology.

[28]  C. Chou,et al.  Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation. , 2014, AJR. American journal of roentgenology.

[29]  S. Bae,et al.  A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma , 2010, The Korean journal of hepatology.

[30]  S. Kawasaki,et al.  The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma , 2010 .

[31]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[32]  J. Jang,et al.  A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management , 2006, Cancer Chemotherapy and Pharmacology.

[33]  M. Ikeda,et al.  Transcatheter Arterial Chemotherapy with and without Embolization in Patients with Hepatocellular Carcinoma , 2004, Oncology.

[34]  W. Ensminger.  Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. , 2002, Seminars in oncology.

[35]  J. Bruix,et al.  Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials , 1999, Hepatology.

[36]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[37]  Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236]. , 2019, Journal of hepatology.

[38]  J. Sicklick,et al.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[39]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.